{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:54:54Z","timestamp":1773312894880,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T00:00:00Z","timestamp":1356566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl J Gynecology &amp; Obste"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare efficacy and tolerability between different regimens of rifaximin vaginal tablets and a placebo for treatment of bacterial vaginosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a prospective study carried out at 13 sites in 3 European countries between August 2009 and October 2010, White, non\u2010pregnant, premenopausal women with bacterial vaginosis were randomly assigned to receive rifaximin at 100 mg for 5 days (100 mg\/5 days), 25 mg\/5 days, or 100 mg\/2 days, or placebo. Women were assessed at 7\u201310 and 28\u201335 days. Diagnosis and cure were based on Amsel criteria and Nugent score. Fisher exact test was used to compare cure rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 114 women recruited, 103 were evaluable for drug efficacy. Therapeutic cure rate at first follow\u2010up was higher in the rifaximin 25 mg\/5 days (48%, <jats:italic>P<\/jats:italic> = 0.04), 100 mg\/2 days (36.0%), and 100 mg\/5 days (25.9%) groups than in the placebo group (19.0%). At second follow\u2010up, therapeutic cure rate was 28.0%, 14.8%, and 4.0% in the respective groups versus 7.7% in the placebo group. No difference in adverse events was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Rifaximin at 25 mg\/5 days showed better therapeutic cure rates and maintenance of therapeutic cure after 1 month versus placebo. All treatment regimens were well tolerated.<\/jats:p><jats:p><jats:bold>EudraCT number: 2009\u2010011826\u201032.<\/jats:bold><\/jats:p><\/jats:sec>","DOI":"10.1016\/j.ijgo.2012.08.022","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T23:05:04Z","timestamp":1356649504000},"page":"131-136","source":"Crossref","is-referenced-by-count":19,"title":["A multicenter, double\u2010blind, randomized, placebo\u2010controlled study of rifaximin for the treatment of bacterial vaginosis"],"prefix":"10.1002","volume":"120","author":[{"given":"Gilbert G.G.","family":"Donders","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Secondo","family":"Guaschino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Tacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Lauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"VARIANT 1 Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318074e565"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2007.01.002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043802"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02884-07"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-11-488"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283021a37"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2000.105738"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001703-200204000-00003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.339"},{"issue":"3","key":"e_1_2_6_11_2","first-page":"CD006055","article-title":"The effects of antimicrobial therapy on bacterial vaginosis in non\u2010pregnant women","author":"Oduyebo O.O.","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/503780"},{"issue":"2","key":"e_1_2_6_13_2","first-page":"256","article-title":"Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial","volume":"96","author":"Paavonen J.","year":"2000","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2008.1088"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70008-1"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000081990"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000081999"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)91112-9"},{"issue":"2","key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/jcm.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation","volume":"29","author":"Nugent R.P.","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"4","key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-0031-1296197","article-title":"Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial","volume":"61","author":"Petersen E.E.","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.11.006"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.06.039"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/OGX.0b013e3181e09621"},{"key":"e_1_2_6_25_2","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).Guidance for Industry Bacterial Vaginosis\u2014Developing Antimicrobial Drugs for Treatment.http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm070969.pdf [Published July 1998]"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000175293.46256.eb"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0020729212005632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0020729212005632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2012.08.022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2012.08.022","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.ijgo.2012.08.022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T08:18:21Z","timestamp":1696407501000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1016\/j.ijgo.2012.08.022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,27]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1016\/j.ijgo.2012.08.022"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgo.2012.08.022","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,27]]}}}